Cadila launches swine flu trials; FDA extends Prevnar 13 review;

Swine Flu

Brazil says it will start producing an H1N1 vaccine in October with plans to initially make 30 million doses of the jab. Story

The WHO says that new cases of Tamiflu-resistant swine flu have appeared. Report

The small biotech Inovio has inked a deal with the NIH's vaccine research group to develop a new universal flu vaccine that could guard against both seasonal influenza and swine flu. The news helped buoy Inovio's stock, which has soared in recent weeks. Story

India's Cadila Pharmaceuticals is seeking regulatory permission to begin clinical trials of a new swine flu vaccine. Report

Mumbai, India's financial capital, has ordered all schools and colleges to close for a week, in the hopes that a shutdown will blunt the spread of the flu. Report

Vaccine Research

The FDA has extended its review of Wyeth's Prevnar 13 for an additional three months, saying it needs more time to review technical data. Sales of the current version of Prevnar hit $2.7 billion last year, and the prospects of earning billions more from the expanded jab was a key motive behind Pfizer's acquisition of Wyeth. Report

The National Institute of Allergy and Infectious Disease has awarded a $2.9 million grant to Hawaii Biotech for the continued development of a new vaccine that can guard against tick-borne encephalitis. Story

Vaccine Market

Nabi Biopharmaceuticals has struck a deal to sell off another big piece of itself. GlaxoSmithKline agreed to pay $46 million--$20 million upfront--for its PentaStaph program, a vaccine in development to guard against hospital-acquired staph infection. The final $26 million will be doled out if the program hits four key milestones. Story

Growing revenue from pediatric and travel vaccines helped Crucell narrow losses for the second quarter. Report

Barron's has taken a close look at Novartis' pipeline and bullishly concluded that the pharma giant has assembled one of the most promising drug pipelines in the industry. And those experimental therapies, including vaccines, are expected to deliver a big bonanza for investors. Report

Only half of all doctors in Texas always recommend the HPV vaccine to girls, despite national guidelines that advise the jab for all girls. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.